Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.

Asano H, Hatanaka KC, Matsuoka R, Dong P, Mitamura T, Konno Y, Kato T, Kobayashi N, Ihira K, Nozaki A, Oku A, Matsuno Y, Hatanaka Y, Watari H.

Ann Surg Oncol. 2019 Dec 2. doi: 10.1245/s10434-019-08103-2. [Epub ahead of print]

PMID:
31792716
2.

Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor.

Zhao G, Wang Q, Wu Z, Tian X, Yan H, Wang B, Dong P, Watari H, Pfeffer LM, Guo Y, Li W, Yue J.

Mol Cancer Ther. 2019 Dec;18(12):2233-2245. doi: 10.1158/1535-7163.MCT-19-0118. Epub 2019 Sep 12.

PMID:
31515295
3.

MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation.

Xu D, Dong P, Xiong Y, Yue J, Ihira K, Konno Y, Kobayashi N, Todo Y, Watari H.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1130. doi: 10.3390/cancers11081130. Review.

4.

Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.

Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, Kobayashi N, Todo Y, Watari H.

J Exp Clin Cancer Res. 2019 Jul 8;38(1):295. doi: 10.1186/s13046-019-1306-9.

5.

Exploring lncRNA-Mediated Regulatory Networks in Endometrial Cancer Cells and the Tumor Microenvironment: Advances and Challenges.

Dong P, Xiong Y, Yue J, J B Hanley S, Kobayashi N, Todo Y, Watari H.

Cancers (Basel). 2019 Feb 16;11(2). pii: E234. doi: 10.3390/cancers11020234. Review.

6.

Correction: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

Oncogene. 2019 May;38(20):3972. doi: 10.1038/s41388-019-0677-x.

PMID:
30679789
7.

Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells.

Ji L, Zhao G, Zhang P, Huo W, Dong P, Watari H, Jia L, Pfeffer LM, Yue J, Zheng J.

J Cancer. 2018 Nov 11;9(24):4578-4585. doi: 10.7150/jca.28040. eCollection 2018.

8.

Molecular-targeted therapies and precision medicine for endometrial cancer.

Mitamura T, Dong P, Ihira K, Kudo M, Watari H.

Jpn J Clin Oncol. 2019 Feb 1;49(2):108-120. doi: 10.1093/jjco/hyy159. Review.

PMID:
30423148
9.

Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.

Dong P, Xiong Y, Yue J, Hanley SJB, Kobayashi N, Todo Y, Watari H.

Front Genet. 2018 Oct 15;9:471. doi: 10.3389/fgene.2018.00471. eCollection 2018. Review.

10.

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Front Oncol. 2018 Sep 19;8:386. doi: 10.3389/fonc.2018.00386. eCollection 2018. Review.

11.

miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway.

Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, Sims M, Li W, Pfeffer LM, Guo Y, Yue J.

J Exp Clin Cancer Res. 2018 Sep 21;37(1):235. doi: 10.1186/s13046-018-0906-0.

12.

B7H3 As a Promoter of Metastasis and Promising Therapeutic Target.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Front Oncol. 2018 Jul 6;8:264. doi: 10.3389/fonc.2018.00264. eCollection 2018. Review.

13.

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

Oncogene. 2018 Sep;37(39):5257-5268. doi: 10.1038/s41388-018-0347-4. Epub 2018 May 31. Erratum in: Oncogene. 2019 Jan 24;:.

14.

miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Oncotarget. 2018 May 1;9(33):23253-23263. doi: 10.18632/oncotarget.25298. eCollection 2018 May 1.

15.

Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.

Aoyama-Kikawa S, Fujita H, Hanley SJB, Kasamo M, Kikuchi K, Torigoe T, Matsuno Y, Tamakoshi A, Sasaki T, Matsuura M, Kato Y, Dong P, Watari H, Saito T, Sengoku K, Sakuragi N.

Cancer Sci. 2018 Jun;109(6):2003-2012. doi: 10.1111/cas.13608. Epub 2018 May 31.

16.

Lentiviral vector mediated-ASAP1 expression promotes epithelial to mesenchymal transition in ovarian cancer cells.

Zhang T, Zhao G, Yang C, Dong P, Watari H, Zeng L, Pfeffer LM, Yue J.

Oncol Lett. 2018 Apr;15(4):4432-4438. doi: 10.3892/ol.2018.7834. Epub 2018 Jan 22.

17.

Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells.

Zhao G, Wang Q, Gu Q, Qiang W, Wei JJ, Dong P, Watari H, Li W, Yue J.

Oncotarget. 2017 Oct 17;8(55):94666-94680. doi: 10.18632/oncotarget.21863. eCollection 2017 Nov 7.

18.

Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.

Dong P, Xiong Y, Hanley SJB, Yue J, Watari H.

J Exp Clin Cancer Res. 2017 Oct 26;36(1):150. doi: 10.1186/s13046-017-0617-y.

19.

Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.

Zhang Q, Dong P, Liu X, Sakuragi N, Guo SW.

Sci Rep. 2017 Jul 28;7(1):6804. doi: 10.1038/s41598-017-06920-7.

20.

iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.

Xiong Y, Sun F, Dong P, Watari H, Yue J, Yu MF, Lan CY, Wang Y, Ma ZB.

J Exp Clin Cancer Res. 2017 Apr 11;36(1):48. doi: 10.1186/s13046-017-0520-6.

Supplemental Content

Loading ...
Support Center